Back to top

messenger-rna: Archive

Zacks Equity Research

Vertex (VRTX) Beats on Q4 Earnings & Sales, '23 View Encouraging

Vertex Pharmaceuticals' (VRTX) four-quarter 2022 earnings and sales beat estimates. VRTX also issues better-than-expected revenue guidance for 2023.

VRTXPositive Net Change MRNAPositive Net Change CRSPPositive Net Change RCUSNegative Net Change

Zacks Equity Research

Vertex (VRTX) to Report Q4 Earnings: What's in the Cards?

On Vertex Pharmaceuticals' (VRTX) Q4 earnings call, investors will likely focus on the sales performance of its cystic fibrosis medicines and updates on its non-CF pipeline candidates.

VRTXPositive Net Change SNDXNegative Net Change CRSPPositive Net Change RCUSNegative Net Change